Novel targeted therapies are needed most urgently for the ABC-DLBCL subtype of lymphomas due to their chemotherapy resistance. In this presentation, I will talk about our efforts in developing specific inhibitors for the CARMA1/Bcl10/ MALT1 and the MyD88/IRAK pathways that lead to NF-kB activation and survival advantage for the lymphomas.<br/>

Targeting NF-kB pathways in toll-like receptor and antigen receptor signaling

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.